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Background: Measurement uncertainty (MU) estimation has been introduced by ISO 15189 for the accreditation
of clinical laboratories. Although MU reporting is not required, its inclusion in medical reports is of potential
assistance to physicians in results interpretation.
Methods: MU reporting was evaluated with respect to diﬀerent test purposes, namely comparison with reference
intervals (RI), patient monitoring or comparison with clinical decision limits. Clinical Biochemistry,
Hematology, Coagulation and Clinical Immunology measurands were used as examples. Assuming Gaussian RI
distribution, the probability of retesting due to MU was determined by simulations. Signiﬁcant MU variations
were compared against the reference change value (RCV) and clinical decision limits.
Results: Three potential scenarios emerged for RI. For 12 measurands, depending on the MU interval, a potential
change in results interpretation was found only for Sodium and S-Protein. On considering only the results within
RI, simulations conﬁrmed that up to 8.6% of MU intervals encompassed the RI limits, thus potentially leading to
retesting. For tests used in patient monitoring, signiﬁcant MU variations were comparable to those calculated by
RCV, with the exception of CEA. For tests results evaluated with respect to clinical decision limits, on including
MU, the clinical interpretation may be improved (e.g. for tPSA).
Conclusion: The ﬁndings made in the present study, which considers real MU data and hypothetical results
obtained for a series of measurands, support the concept that MU may aid the physician's interpretation thus
ensuring reliable clinical decision making.
1. Introduction
Medical laboratories should guarantee that laboratory reports con-
tain all the information required for the correct interpretation of tests
results. In laboratory medicine the communication of results to physi-
cians, a process included in the post-analytical phase, is of crucial im-
portance, as the interpretation of results is always performed as a
comparison. For this purpose, a series of diﬀerent types of information,
usually included in laboratory reports in order to facilitate the inter-
pretation of test results, includes the measurand reference interval (RI),
diagnostic cut-oﬀs and decision limits, as well as the reference change
value (RCV), where appropriate. However, as stated by the Guide to the
expression of Uncertainty in Measurement (JCGM 100:2008) “the result
of a measurement is only an approximation or estimate of the value of
the measurand and thus is completed only when accompanied by a
statement of the uncertainty of that estimate” [1]. In recent years, with
the adoption of ISO 15189:2012 for the accreditation of medical la-
boratories, a requirement made is the estimation of measurement
uncertainty (MU) [2]. Nevertheless, the ISO 15189:2012 does not
specify methods for estimating MU, and the inclusion or exclusion of
MU in laboratory reports is left to the laboratory's discretion, the ISO
15189:2012 only stating that “Upon request, the laboratory shall make
its estimates of measurement uncertainty available to laboratory users”
[2]. However, the reporting of MU in medical reports does call for
considerations to be made and discussed in advance by laboratory
medicine experts, in order to guarantee that physicians are provided
with the support needed for the correct interpretation of test results. In
fact, the reporting of MU may eﬀect a modiﬁcation of test result in-
terpretation and of clinical reasoning. Moreover, as recently pointed
out, when using MU to assist results interpretation (according to ISO
15189:2012), it is also important to choose the most appropriate
available model according to the ﬁt-for-purpose of tests [3–5].
In order to ascertain the appropriateness of including the MU in
laboratory medical reports, the modality to use, and to focus on how
this information could inﬂuence the interpretation of test result, the
present paper reports on and evaluates a series of diﬀerent scenarios
https://doi.org/10.1016/j.clinbiochem.2018.03.009
Received 24 November 2017; Received in revised form 12 March 2018; Accepted 12 March 2018
⁎ Corresponding author at: Department of Medicine – DIMED, University of Padova, via Giustiniani 2, 35128 Padova, Italy.
E-mail address: andrea.padoan@unipd.it (A. Padoan).
Clinical Biochemistry xxx (xxxx) xxx–xxx
0009-9120/ © 2018 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
Please cite this article as: Padoan, A., Clinical Biochemistry (2018), https://doi.org/10.1016/j.clinbiochem.2018.03.009
regarding the role of MU in test results interpretation, when the at-
tention is focused on RIs, clinical decision points and RCV, respectively,
as shown in Table 1. This study requires skills both on essentials and
advanced statistical concepts, such as probability distributions, mean
and standard deviation, percentiles and the Monte Carlo simulations,
and methods for understanding and implementing the proposed ap-
proach, but in another paper, a proposal for “what information on
measurement uncertainty should be communicated to clinicians, and
how” is available as guidance as to how the outcome of this type of
study are applicable to clinical laboratories [6].
2. Materials and methods
Two assumptions regarding RI were made in this study: a) the RI
distributions are assumed to be Gaussian, b) RI, established by either
the laboratory or the manufacturer, are carefully veriﬁed by the la-
boratory. In this context, the total variance of the distribution of re-
ference values consists of: biological (intra-individual, SD2I , and inter-
individual, SD2G, variance) and analytical (SD2A) variation and for each
individual, both the distribution values around the personal homeo-
static set-points, with variance SD2I and the distribution homeostatic
set-points of the reference population, with variance SD2G, can been
considered normal [7–9]. Based on these considerations, and given a
measurand, the variance attributable to the distribution of the reference
values (SD2T), can be calculated by SD2T= SD2A+ SD2I + SD2G, and SD2T
can be derived by using RI with the following formula
SD2T= (URL− LRL)/3.92, where URL and LRL are the upper and the
lower RI limits, respectively, and 3.92 derived from the z factor 1.96
multiplied by 2, for a RI covering the 95% interval of the reference
values [10,11]. The reference population mean can be derived by
mean= (URL+LRL)/2. Therefore, by assuming a) and b), a test result
between mean ± 2 ∗ SDT is within its RI [10]. Imprecision was esti-
mated by using the long-term IQC data (of the latest 6 months), while
the expanded MU was estimated by applying the Nordtest approach,
with further detailed information available in a previous publication
[5,12]. Brieﬂy, MU were estimated by including imprecision or a
combination of imprecision, bias and bias uncertainty, depending on
the ﬁt-for-purpose of test results (Table 1). The weighted average of
IQCs variance were used as imprecision, while bias and bias uncertainty
were estimated by External Quality Assessment schemes (EQAs) [5].
The approach used was ﬂexible and feasible, based on the data avail-
able for each measurement procedure. Measurement bias was estimated
using commutable EQA materials where target values were assigned
using high order reference materials and/or reference measurement
procedures. If such materials were not available, the consensus value
related to the speciﬁc diagnostic system was used [5].
The Index of Individuality (II) was calculated using the formula
(CV2A+CV2I )1/2/CVG from Petersen et al. [13].
Monte Carlo analyses were performed by simulating random gen-
erated normal distribution of n= 200 values. For each measurand
considered in the simulation, normally distributed data were generated
by using the mean and the total standard deviation, calculated using the
above formulas. Finally, for any test result included in the interval
between URL and LRL, a total of 1000 iterations were performed to
calculate the probability that the corresponding MU interval would
include the upper or lower RI (pinc). The Monte Carlo standard error
estimate of pinc was also calculated using the standard deviation of pinc.
For the same measurands used in the Monte Carlo simulations, data
from the Laboratory Information System (LIS) of the Department of
Laboratory Medicine of the University-Hospital of Padova where ob-
tained, in a time period of 2months (from November to December
2017). For the following measurands ALT, Sodium, Potassium, Urea,
Cholesterol, Iron, Hemoglobin and MCV results from outpatients (non-
hospitalized subjects referring directly to the laboratory for blood
testing) were included; for Lactate, S-Protein, C-Protein and D-Dimer,
also the inpatients (hospitalized patients) were included, due to the
limited number of determinations for these measurands in the group of
the outpatients. For test results included in the interval between URL
and LRL, the real percentage of MU intervals that would include the
upper or lower RI were estimated.
Bidirectional, 95% probability reference change value (RCV) was
calculated using the formula RCV=21/2 ∗ Z ∗ (CV2A+CV2I )1/2 [14],
while the MU critical diﬀerence was derived through multiplying the
corresponding MU by a factor equal to 2.83, which allows two serial
measurements and the two corresponding MU to be taken into account
when a test result is used mainly for monitoring patients over time [15].
Data for biological within- and between-subject variations were
obtained with the Westgard database on biological variation (https://
www.westgard.com/biodatabase1.htm, accessed on May 2017). R for
statistical computing v 3.3.1 software, (Statistical Computing, Vienna,
Austria) and Microsoft Excel (Microsoft® Corporation, Redmond,
Washington, USA) were used for the statistical analyses.
3. Results
3.1. Test results compared with established (or veriﬁed) RI
On considering hypothetical test results lying around the upper re-
ference limit (URL) of the distribution of reference values (e.g. at values
equal to mean plus 1.5, 2 or 2.5 times SD2T), diﬀerent scenarios may
emerge when MU was included in the laboratory report (Fig. 1) and
considered for test interpretation. The ﬁrst, more straightforward Sce-
nario 1 regards the situation in which the test result (x) overlaps to URL
(x=mean+2 ∗ SDT) (Fig. 1, panel A). The MU interval spreads 50% to
the left and 50% to the right of test results, irrespective of the MU in-
terval extent and the extent of biological and analytical variations. In
this case, if a repeat test is requested on the same sample, the prob-
ability of the new result being inside or outside RI should be equal.
Other hypothetical scenarios are represented by test results within RI
(Scenario 2) or above the URL (Scenario 3). An example of the former
case is when a hypothetical test result is at x=mean+ 1.5 SDT; once
observed with its MU, the MU interval may include the upper reference
interval limit (Fig. 1, panel B). Likewise, also in Scenario 3 the MU
interval may include the URL (Fig. 1, panel C). Scenarios 2 and 3 re-
present the two situations in which the inclusion of MU in the test result
might lead to diﬀerent clinical conclusions. In Scenarios 2 and 3, the
contribution of MU to results interpretation became relevant when the
ratio of SDA/SDT was elevated.
Table 2 shows data that include biological (expressed as CV) and
analytical variation, calculated by internal quality control (IQC), and
Table 1
Test purposes and uncertainty. Clinically signiﬁcant components for estimating measurement uncertainty for the diﬀerent tests purposes.
Test purpose Examples Components to include in measurement
uncertainty
Primarily for monitoring patients over time E.g. tumour markers, immunosuppressive
drugs
Imprecision only [3,4]
Comparison with reference intervals, either established in the same laboratory or
veriﬁed in the laboratory using appropriate procedures
E.g. hormones Imprecision only [3]
Usually compared with a clinical decision point E.g. glucose, ions Imprecision, bias and bias uncertainty [3]
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the MU obtained on evaluated measurands. As shown in Table 1, MU
was calculated by using analytical variation alone. An example of this is
Sodium, for which the RI was 136mmol/L to 145mmol/L: on con-
sidering a hypothetical result of 146.2 mmol/L (Scenario 3), the
corresponding interval of results (obtained by using MU) was between
144mmol/L and 148.5 mmol/L, thus including the URL (145mmol/L).
Likewise, for Sodium values of 143.9mmol/L (Scenario 2, representing
mean+1.5 ∗ SDT), the results interval is 141.7–146.2 mmol/L, URL
Fig. 1. Reference intervals limits, expanded measurement uncertainty (MU) and test results interpretation. The same Gaussian distributed reference interval (RI) is shown with its upper
and lower limits (URL and LRL, respectively), estimated by the formulas reported in Materials and Methods. Figure reports the three possible diﬀerent scenarios obtained by the inclusion
of MU to laboratory report (panels A, B and C). Panel A represents the situation when a test result is equal (overlapped) to the upper reference limit (URL), Scenario 1. Panel B illustrates a
hypothetical test result within RI, Scenario 2. Panel C illustrates a hypothetical test result above the URL, Scenario 3. For each panel, two diﬀerent MU were superimposed to the
distribution of reference values; on the left a smaller MU (width equal to 0.1× SDT), on the right a larger MU (width equal to 0.185×SDT) are shown both as means of probability
distribution but also as conﬁdence limits (vertical dashed lines).
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again included. On considering the 12 measurands shown in Table 2, a
similar situation was found only for S-Protein. The highest SDA/SDT
ratios were those for Sodium and for S-Protein (Table 2). In order to test
the hypothesis that the SDA/SDT ratio was associated with the prob-
ability of having one RI included in the MU interval, a series of Monte
Carlo simulations were performed. In this iterated analysis, the prob-
ability that the MU intervals included the URL (pinc) was calculated
only for tests results between URL and the lower reference limit (LRL);
the results, reported in Table 3, show that the ratios SDA/SDT were
closely correlated with pinc (Spearman r=0.995, p < 0.01), these
probabilities ranging from 8.61% of Sodium to 0.18% of Hemoglobin.
However, the Individuality Index (II) was not associated with pinc.
These simulation results undertaken the assumptions that the within-
and the between-subjects variance are normally distributed; in order to
evaluate the transferability of these ﬁndings into real life, a large series
of data were obtained from the Laboratory Information System (LIS) for
the same measurands evaluated by simulations. For each measurand,
the real percentage of MU intervals that would include the upper or
lower RI were calculated and reported in Table 3. By carefully evalu-
ating Q-Q plots, especially for ALT, Lactate, Urea, Iron, MCV, S-Protein,
C-Protein and D-dimer, a skewed data distribution was found with re-
spect to the normal distributed data of Na, K, Cholesterol, Hemoglobin.
A ﬁnal consideration to make is that all the results obtained for the
URL will be identical to those to be obtained on considering the lower
limit of RIs, due to assumption of RI distribution symmetry.
3.2. Tests results compared with a previous result in patient monitoring
Table 4 shows examples of measurands with their signiﬁcant var-
iations, calculated by using both RCV and MU, with respect to their
decision limits. With the exception of CEA, signiﬁcant MU diﬀerences
were lower (albeit for some measurands the diﬀerence was slight) than
those obtained for signiﬁcant RCV diﬀerences, for all the studied
measurands.
3.3. Tests results compared with a diagnostic decision level
Table 5 reports examples of some measurands with their signiﬁcant
variation calculated with respect to the diagnostic decision level. For
tPSA, the calculated MU was 1 μg/mL; negative results are therefore
those ≤3 μg/mL. On the contrary, a tPSA value of> 3 μg/mL possibly
becomes positive if interpreted by considering MU. Analogously, a
value of 6.8 mmol/L of glucose will possibly be positive when MU is
included with the test result.
4. Discussion
Medical laboratory reports contain laboratory test results and the
information necessary to enable requesting physicians to make the
correct interpretation; this, in turn, is of crucial importance in reliable
clinical decision making and providing eﬀective patient care.
Therefore, it is of paramount importance that the information provided
is clear, concise and fully interpretative, as the format, the content and
the communication strategies of laboratory reports signiﬁcantly aﬀect
the interpretation and utilization of laboratory data by clinicians [16].
ISO 15189:2012 accreditation introduces the estimation of MU for
the measurement procedure, which provides a quantitative overview of
the quality of a test result [17]. ISO 15189:2012 states that MU should
be readily available, while laboratories are not obliged to include MU in
their reports. Yet, at least in some speciﬁc clinical settings, MU might
improve clinical decision making, contributing to ameliorating patient
care [17]. Including MU in a test result should prompt the clinician to
shift focus from the actual numerical value (the result) to a surrounding
interval of probable results as, for simplicity, MU could be viewed as the
conﬁdence that can be placed in a test result. From this viewpoint, it is
important to bear in mind that the importance MU calculation mayTa
bl
e
2
R
es
ul
ts
ob
ta
in
ed
fo
r
a
se
ri
es
of
12
ill
us
tr
at
iv
e
m
ea
su
ra
nd
s,
fo
r
th
e
C
lin
ic
al
Bi
oc
he
m
is
tr
y
an
d
H
em
at
ol
og
y
an
d
C
oa
gu
la
ti
on
ar
ea
s.
Tw
o
hy
po
th
et
ic
al
se
ri
es
of
re
su
lt
s
w
er
e
co
ns
id
er
ed
,t
he
ﬁ
rs
ta
tm
ea
n
+
2.
5
×
SD
T
an
d
th
e
ot
he
r
at
m
ea
n
+
1.
5
×
SD
T
(B
),
w
it
h
th
ei
r
co
rr
es
po
nd
in
g
M
U
in
te
rv
al
s,
w
hi
ch
ar
e
co
m
pa
re
d
to
co
rr
es
po
nd
in
g
R
I.
D
at
a
fo
r
bi
ol
og
ic
al
va
ri
at
io
n
an
d
th
e
in
di
vi
du
al
it
y
in
de
x
(I
I)
ar
e
al
so
in
cl
ud
ed
.
M
ea
su
ra
nd
s
W
es
tg
ar
d
BV
a
IQ
C
da
ta
In
de
x
of
In
di
vi
du
al
it
y
R
ef
er
en
ce
In
te
rv
al
(R
I)
lim
it
s
To
ta
l
st
an
da
rd
de
vi
at
io
nb
SD
A
/S
D
T
M
U
c
H
yp
ot
he
ti
ca
ls
re
su
lt
M
U
in
te
rv
al
H
yp
ot
he
ti
ca
ls
re
su
lt
M
U
in
te
rv
al
C
V
I
C
V
G
C
V
A
SD
A
Lo
w
er
U
pp
er
SD
T
2.
5
SD
T
Lo
w
er
lim
it
U
pp
er
lim
it
1.
5
SD
T
Lo
w
er
lim
it
U
pp
er
lim
it
A
LT
(U
/L
)
19
.4
41
.6
4.
4
1.
7
0.
48
10
50
10
.2
0.
17
3.
4
55
.5
52
.1
58
.9
45
.3
41
.9
48
.7
La
ct
at
e
(m
m
ol
/L
)
27
.2
16
.7
2.
4
0.
04
1.
64
0.
5
2.
2
0.
4
0.
09
0.
10
2.
4
2.
4
2.
5
2.
0
1.
9
2.
1
So
di
um
(m
m
ol
/L
)
0.
6
0.
7
0.
9
1.
13
1.
55
13
6
14
5
2.
3
0.
49
2.
26
14
6.
2
14
4.
0
14
8.
5
14
3.
9
14
1.
7
14
6.
2
Po
ta
ss
iu
m
(m
m
ol
/
L)
4.
6
5.
6
0.
7
0.
03
0.
83
3.
4
4.
5
0.
3
0.
11
0.
06
4.
7
4.
6
4.
7
4.
4
4.
3
4.
4
U
re
a
(m
m
ol
/L
)
12
.1
18
.7
2.
3
0.
12
0.
66
2.
5
7.
5
1.
3
0.
09
0.
24
8.
2
7.
9
8.
4
6.
9
6.
7
7.
2
C
ho
le
st
er
ol
(m
m
ol
/L
)
5.
95
15
.3
1.
3
0.
06
0.
40
2
6.
19
1.
1
0.
06
0.
12
6.
8
6.
6
6.
9
5.
7
5.
6
5.
8
Ir
on
(μ
m
ol
/L
)
26
.5
23
.2
1.
22
0.
2
1.
14
11
.6
31
.3
5.
0
0.
04
0.
4
34
.0
33
.6
34
.4
29
.0
28
.6
29
.4
H
em
og
lo
bi
n
(g
/L
)
2.
85
6.
8
0.
82
0.
14
0.
44
14
0
17
5
8.
9
0.
02
0.
28
17
9.
8
17
9.
5
18
0.
1
17
0.
9
17
0.
6
17
1.
2
M
C
V
(f
L)
1.
4
4.
85
0.
7
0.
55
0.
32
80
96
4.
1
0.
13
1.
1
98
.2
97
.1
99
.3
94
.1
93
.0
95
.2
S-
Pr
ot
ei
n
(%
)
5.
8
63
.4
2.
6
5.
5
0.
10
74
14
6
18
.4
0.
30
11
15
5.
9
14
4.
9
16
6.
9
13
7.
6
12
6.
6
14
8.
6
C
-P
ro
te
in
(%
)
5.
6
55
.2
2.
9
0.
77
0.
11
70
14
0
17
.9
0.
04
1.
54
14
9.
6
14
8.
1
15
1.
2
13
1.
8
13
0.
2
13
3.
3
D
-D
im
er
(μ
g/
L)
23
.3
26
.5
6.
25
16
.8
0.
91
0
40
0
10
2.
0
0.
16
33
.6
45
5.
1
42
1.
5
48
8.
7
35
3.
1
31
9.
5
38
6.
7
BV
=
bi
ol
og
ic
al
va
ri
at
io
n;
C
V
I
=
in
tr
a-
su
bj
ec
t
bi
ol
og
ic
al
va
ri
at
io
n;
C
V
G
=
in
te
r-
su
bj
ec
t
bi
ol
og
ic
al
va
ri
at
io
n;
C
V
A
=
an
al
yt
ic
al
va
ri
at
io
n
ca
lc
ul
at
ed
us
in
g
IQ
C
av
ai
la
bl
e
da
ta
.T
V
w
as
ca
lc
ul
at
ed
as
su
gg
es
te
d
by
H
ae
ck
el
et
al
.[
9]
.
a
D
er
iv
ed
fr
om
W
es
tg
ar
d
on
lin
e
da
ta
ba
se
(h
tt
ps
:/
/w
w
w
.w
es
tg
ar
d.
co
m
/b
io
da
ta
ba
se
1.
ht
m
,a
cc
es
se
d
on
M
ay
20
17
).
b
D
er
iv
ed
fr
om
R
Is
as
de
sc
ri
be
d
in
M
at
er
ia
ls
an
d
m
et
ho
ds
.
c
C
al
cu
la
te
d
us
in
g
on
ly
SD
A
.
A. Padoan et al. Clinical Biochemistry xxx (xxxx) xxx–xxx
4
diﬀer depending upon the primary clinical application of the test result,
as recently stated in the literature, and summarized in Table 1 [3,4,17].
This approach consists on the inclusion of imprecision, or a combina-
tion of imprecision, bias and bias uncertainty in MU. However, it should
be noted that reagents lot-to-lot variability can deliver bias (that will
possibly appear in IQC and external quality assessment data, shifting
the reference points during time), possibly delivering a further source of
error, especially considering the aim of improving the overall decision
making based on sound analytical and metrological principles. In this
study, for estimating MU we used the approach we have recently used
to estimate measurement uncertainty in our laboratory to achieve the
accreditation according to ISO 15189:2012 [5]. This approach attracted
many criticisms from ISO 15189 accreditors, especially because JCGM
100:2008 stated that for MU steps are to be taken to minimize bias, e.g.
by recalibration [1]. However, the discussion on bias remains still open
and Theodorson E. in a recent work stated that “Among myths about
measurement uncertainty methods is that they demand that bias be
eliminated before uncertainty calculations and estimated can be made.
Uncertainty approaches claim that bias should be eliminated when
identiﬁed. However, if bias cannot be eliminated, or when bias elim-
ination risks increasing the overall measurement uncertainty, this can
be handled as any other type B uncertainty” [19]. Further, despite bias
should be ideally estimated relative to the reference material or re-
ference measurement procedure that was used through a calibration
hierarchy to assign the value of the end-user calibrator of the routine
measurement procedure being considered, this approach can be cur-
rently applied only to few measurands. Therefore, in this study, in the
absence of reference materials or reference measurement procedures,
the diagnostic system was used, thus allowing to reduce the variability
due to a mix of diﬀerent measurement methods and procedures [5].
The possible advantages or disadvantages of including MU in
medical laboratory reports have not yet been adequately discussed,
although the potential utility of MU in clinical decision-making is ad-
vocated in ISO 15189:2012 as well as other manuscripts available in
literature [2,17–19]. The present study takes into account some real
Table 3
Monte Carlo simulation results and, in comparison, real data results calculated by using the Laboratory Information System, for the measurands of the Clinical Biochemistry and
Hematology and Coagulation areas included in the study.
SDA SDT SDA/SDT RIs Monte Carlo Simulation Results Real data results
Probability that MU includes RIs
(pinc) (%)
SEa of pinc
(%)
Total number of
observations
Percentage of MU that includes
RIs (%)
ALT (U/L) 1.7 10.2 0.17 10–50 2.51 0.05 526 2.88
Lactate (mmol/L) 0.04 0.4 0.09 0.5–2.2 1.32 0.04 669 3.51
Sodium (mmol/L) 1.13 2.3 0.49 136–145 8.61 0.09 2540 8.80
Potassium (mmol/L) 0.03 0.3 0.11 3.4–4.5 1.32 0.03 2808 1.6
Urea (mmol/L) 0.12 1.3 0.09 2.5–7.5 1.20 0.03 1919 0.94
Cholesterol (mmol/L) 0.06 1.1 0.06 2–6.19 0.65 0.02 3455 0.75
Iron (μmol/L) 0.2 5.0 0.04 11.6–31.3 0.47 0.02 1617 0.42
Hemoglobin (g/L) 0.14 8.9 0.02 140–175 0.18 0.01 7896 0.22
MCV (fL) 0.55 4.1 0.13 80–96 1.89 0.04 7896 1.63
S-Protein (%) 5.5 18.4 0.30 76–146 5.76 0.07 356 12.9
C-Protein (%) 0.77 17.9 0.04 70–140 0.51 0.02 338 1.2
D-Dimer (μg/L) 6.25 102 0.16 0–400 2.47 0.05 3905 1.5
For a series of illustrative measurands, reference intervals (RIs), analytical (SDA), total (SDT) variation and the ratio between SDA and SDT are reported. For each measurand, Pinc is the
probability that any “normal test result” (falling inside RIs) will have MU intervals that include the upper (or lower) RIs limit (pinc). This is the probability of obtaining a particular test
result in which its MU includes one (not both) of the RIs limits.
a pinc standard errors (SE) are derived from the distribution of Monte Carlo results. Monte Carlo runs= 10,000. Real data were obtained by the Laboratory Information system of the
Department of Laboratory Medicine of the University-Hospital of Padova in a time period from November to December 2017.
Table 4
Signiﬁcant variations calculated for six illustrative measurands, considering both reference change value (RCV) and measurement uncertainty (MU) with respect to a hypothetical result
at clinical decision cut-oﬀ.
Measurands Westgard BVa IQC data Index of Individuality (II) MUb Hypothetical result at decision limit Signiﬁcant variation based on:
CVI CVG CVA RCVb MUb
CEA (μg/L) 12.7 55.6 3.7 0.24 1.4 5.0 6.8 7.0
CA 15–3 (kU/L) 6.1 62.9 3.8 0.11 3.2 37.5 45.0 42.0
CA 125 (kU/L) 27.4 54.6 4.5 0.51 9.2 48.0 84.9 61.0
CA 19–9 (kU/L) 16.0 130.5 8.7 0.14 5.2 37.0 55.7 44.3
AST (U/L) 12.3 23.1 2.5 0.54 11.0 45 60.7 60.5
Creatinine (umol/l) 5.95 14.7 1.2 0.41 4.0 104 121.3 109.7
BV=biological variation; CVI= intra-subject biological variation; CVG= inter-subject biological variation; CVA= analytical variation calculated using available IQC data, expressed as
percentage.
a Derived from the Westgard online database.
b Calculated as described in Materials and methods.
Table 5
Signiﬁcant limits for MU intervals of four illustrative measurands, with respect to their
corresponding decision limits.
Measurand IQC data MUa Decision limit Signiﬁcant limit for MU
CVA Cut-oﬀ Lower limit Upper limit
Glucose (mmol/L) 1.5 0.4 7 6.6 7.4
tPSA (μg/L) 3.7 1.0 4 3.0 5.0
HbA1c (mmol/
mol)
1.7 3.6 48 44.4 51.6
Troponin I (ng/L) 7.0 2.7 16 13.3 18.7
CVA= analytical variation calculated using IQC data; HbA1c= glycated hemoglobin;
tPSA= total prostate speciﬁc antigen level.
a Calculated as described in Materials and methods.
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MU data, in addition to a series of hypothetical results for some
common measurands, and evaluates the diﬀerences in clinical inter-
pretations given to the combination of test results and their MU values.
Firstly, we considered the interpretation of a test result with respect
to a reference interval that had been either established or veriﬁed by
the laboratory; in this case, MU estimation should include only im-
precision (Table 1). Three scenarios can be identiﬁed (Fig. 1). In theory,
Scenario 2 may include situations in which, although the test result falls
within the RI range, the MU interval could include the URL (or LRL). In
this situation, based on the inclusion of the MU interval, the clinical
interpretation of test results should take the patient's clinical data into
account. As shown in Table 2, sodium (but not potassium), could be
involved in situations like Scenario 2, and a sodium value of 144mmol/
L, with its MU, could encompass (and exceed) the upper reference limit
(145mmol/L). Although the MU interval does not include critical va-
lues for sodium, patients might be considered alternatively in a
“normal” or in borderline hypernatraemia conditions, depending on the
interpretation given to MU. However, to assure patient safety, parti-
cularly in critical circumstances, clinicians may decide to correct so-
dium levels on the basis on an initial hypernatremia. Interestingly, if a
test result and its MU value are not interpreted in the right clinical
setting, Scenario 2 might induce clinicians to request the re-testing of a
specimen. Table 3 reports, for the series of measurands evaluated, the
probability that a “normal” subject, with a test result falling within RI,
will have MU that encompass at least one of the RIs limits. This prob-
ability (pinc) speciﬁcally indicates that a test result may be retested due
to misinterpretation arising from the inclusion of the MU interval in the
laboratory report; this is extremely unlikely for several measurand,
especially those with a low SDA/SDT ratio. Pinc values were then com-
pared with the real percentage calculated on a series of laboratory re-
sults retrieved from the LIS and, irrespective on data distribution, re-
sults for the majority of measurands were overlapping.
In addition, another aspect that may be consider regards the little
utility of using RI for that measurands with II is< 0.6 (or> 1.4). This
fact should not limit the clinical utility of MU as we found that pinc is
not associated to II. However, as stated by ISO 15189:2012, the MU
value, calculated for each quantitative measurement procedure, is
considered of practical utility to clinicians when the interpretation of
test results is used as “meaningful comparison of a patient value with a
previous value of the same type or with a clinical decision value” [2].
Therefore, the limitations given by measurands individuality on RI does
not inﬂuence MU interpretation.
The case is diﬀerent when test results are used for monitoring dis-
ease, the interpretation being made mainly by comparison with a pre-
vious result. It is also important to bear in mind that in this situation
imprecision alone should be included in the MU estimation because,
their bias being similar for both measurements will be cancelled.
Table 4, which reports data for some measurand commonly used for
monitoring the patient's disease status, shows that the signiﬁcant RCV
variation is generally wider than that of MU. Therefore, in these si-
tuations (e.g. for tumour markers), MU is not of clinical utility, the RCV
being the most appropriate value to be considered. Importantly, ther-
apeutic drug monitoring (TDM) is a completely diﬀerent case, and MU
(not RCV) should be considered for determining diﬀerences in serial
measurements.
Where a test result is compared with a clinical decision point, the
MU calculation should include bias (Table 1). Table 5 lists some mea-
surands in this category, such as glucose, cardiac troponin, tPSA and
HbA1c. For these measurands, the interpretation of patients' results is
mainly performed by comparison with respect to a deﬁned clinical
decision point. At least for some of these measurands, such as Glucose
and tPSA, the clinical interpretation of test results could diﬀer if MU is
included in laboratory reports. For example, the diagnostic cut-oﬀ of
fasting plasma glucose (FPG) for diabetes mellitus diagnosis is
7.0 mmol/L; the lower limits obtained by MU (0.4mmol/L) for a value
of 7.0mmol/L become 6.6mmol/L. Therefore, the clinician may
consider an FPG result ranging between 6.6mmol/L and 7.0mmol/L as
an initial alert suggesting diabetes. Yet there are other ways of enabling
a diagnosis of diabetes, such as 1) repeating FPG after a few weeks, 2)
conﬁrming diabetes by either evaluating the HBA1c result or requesting
a 75 g oral glucose tolerance test [20]. Diﬀerently, patients with ele-
vated tPSA (i.e.> 4 ng/mL) and/or suspicious signs at digital rectal
examination are eligible for prostate biopsy, especially if elderly [21].
Table 4 shows that the tPSA MU is 1 ng/mL. Therefore, with a value of
tPSA > 3 ng/mL, the probability of having a real value above 4 is not
null and, according to the European Association of Urology (EAU)
guidelines, the clinician can consider the opportunity of requesting a
veriﬁcation of PSA levels after a few weeks to exclude persistently
elevated tPSA, which calls for prostate biopsy, thus ensuring that the
diagnostic workup is more reliable [21].
In conclusion, the present paper bears out that the reporting of MU
in medical laboratory reports can improve the clinical decision making.
The results obtained, which suggest how to calculate MU in diﬀerent
situations, and for a series of diﬀerent measurands, conﬁrm the concept
that physicians can adjust their decisional level by giving a more ac-
curate interpretation of MU of a test, in order to facilitate clinical de-
cision-making and maximise patient safety. The reduction in analytical
variability should be emphasised, because the ratio SDA/SDT seems to
represent a measure of how MU can provide “weight” in the frequency
of interpretation of test results related to MU inclusion in laboratory
reports.
Finally, this study has some drawbacks, such as the assumption of
normality of distribution of RIs, and the limited number of measurands
considered. In addition, data on biological variation used this study
may indeed be ﬂawed, as recently underlined by ﬁndings of the EFLM
Working group on Biological Variation, which are delivering an up-
dated estimated of these values Therefore, other insights should be
considered to support the results reported in this study, including new
data generated on biological variation which may provide a more evi-
dence-based information [22]. Results obtained in Scenario 1–3 may be
replicated to other measurands, namely those with a log-normal dis-
tributed data [10].
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